JMP Securities Cuts Haemonetics (NYSE:HAE) Price Target to $100.00

Haemonetics (NYSE:HAE) had its target price reduced by JMP Securities from $125.00 to $100.00 in a research note published on Friday morning,Benzinga reports. They currently have a market outperform rating on the medical instruments supplier’s stock.

Other analysts also recently issued reports about the company. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $95.00 to $68.00 in a report on Friday. Needham & Company LLC reduced their price target on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a report on Friday. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective on the stock in a research note on Friday, November 8th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. Finally, Barrington Research reduced their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $101.67.

Haemonetics Trading Down 5.8 %

Shares of HAE opened at $59.34 on Friday. Haemonetics has a 1 year low of $59.09 and a 1 year high of $97.97. The company has a 50 day simple moving average of $76.38 and a two-hundred day simple moving average of $78.32. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.09. The firm has a market cap of $2.98 billion, a P/E ratio of 23.36, a price-to-earnings-growth ratio of 0.98 and a beta of 0.39.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, equities analysts expect that Haemonetics will post 4.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Large investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC lifted its holdings in shares of Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 632 shares during the last quarter. Parkside Financial Bank & Trust lifted its stake in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 240 shares during the last quarter. AlphaQuest LLC boosted its holdings in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after acquiring an additional 1,826 shares during the period. KBC Group NV grew its position in shares of Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 712 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new position in shares of Haemonetics in the 3rd quarter valued at $204,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.